Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $85M (up 71.1% year over year) with net income of −$14M.
Q3 2026 key financials · XBRL
- Revenue
- $85M
- +71.1% YoY · +14.1% QoQ
- Net income
- −$14M
- +53.6% YoY · +21.0% QoQ
- Operating margin
- -0.1%
- Gross margin
- 78.3%
- EPS (diluted)
- −$0.16
- +60.0% YoY · +23.8% QoQ
Source: XBRL data from the Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 10-Q on SEC EDGAR. USD.
Phathom Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $84.7M, up $35.2M from $49.5M YoY, driven by VOQUEZNA products
- Gross margin 78.3% vs 87.5% YoY, with cost of revenue $18.4M vs $6.2M
- Net loss $13.9M vs $30.0M YoY, operating loss $0.1M vs $15.3M
- Cash $184.6M; nine-month operating cash outflow $15.7M vs $161.8M YoY
- Outlook: cash and anticipated product revenues sufficient for operations at least twelve months; EoE topline results expected fourth quarter 2026
Risk Factors
- New litigation risk: BDR challenged FDA’s GAIN Act extension of VOQUEZNA exclusivity through May 3, 2032
- Regulatory risk: adverse ruling could enable earlier ANDA submissions and generic competition
- Market risk: earlier generics could materially reduce VOQUEZNA sales, pricing and market share
- Legal risk: Saba intends to seek consolidation of a related challenge with BDR’s lawsuit
- Operational risk: litigation and FDA proceedings may be lengthy, costly and distracting to management
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Phathom Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.